BioCentury | Jun 2, 2017
Emerging Company Profile

Prolonging thrombin production

...hemophilia A. Baglin and Huntington have co-founded two other anticoagulation companies backed by Medicxi, including SuperX Ltd....
...Haemostasis (ISTH), Carrboro, N.C. National Hemophilia Foundation, New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland SuperX Ltd....
BioCentury | Feb 11, 2017
Finance

Dynamic duo

...helmed are sold. But few have been as prolific in as short a time as SuperX Ltd.’s...
...so compelling that we had to bend the model to pursue them.” David Grainger, Medicxi SuperX...
...undisclosed sum (see BioCentury, March 30, 2015) . Johnson & Johnson Innovation-JJDC Inc. participated in SuperX’s...
BioCentury | Feb 10, 2017
Financial News

SuperX completes venture financing

...Anticoagulation play SuperX Ltd. (Cambridge, U.K.) raised $11 million in a series A round led by Medicxi...
...Medicxi on Feb. 9. Johnson & Johnson Innovation-JJDC Inc. also participated. SuperX Ltd. , Cambridge, U.K. Alex Himes SuperX Ltd....
BioCentury | Feb 9, 2017
Financial News

SuperX raises $11M series A round

...Anticoagulation play SuperX Ltd. (Cambridge, U.K.) raised $11 million in a series A round led by Medicxi...
...of bleeding. The company expects to begin clinical studies of its lead program in 2019. SuperX's...
...region of thrombin also dissociates anticoagulation from bleeding risk (see BioCentury, March 30, 2015) . SuperX...
Items per page:
1 - 4 of 4
BioCentury | Jun 2, 2017
Emerging Company Profile

Prolonging thrombin production

...hemophilia A. Baglin and Huntington have co-founded two other anticoagulation companies backed by Medicxi, including SuperX Ltd....
...Haemostasis (ISTH), Carrboro, N.C. National Hemophilia Foundation, New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland SuperX Ltd....
BioCentury | Feb 11, 2017
Finance

Dynamic duo

...helmed are sold. But few have been as prolific in as short a time as SuperX Ltd.’s...
...so compelling that we had to bend the model to pursue them.” David Grainger, Medicxi SuperX...
...undisclosed sum (see BioCentury, March 30, 2015) . Johnson & Johnson Innovation-JJDC Inc. participated in SuperX’s...
BioCentury | Feb 10, 2017
Financial News

SuperX completes venture financing

...Anticoagulation play SuperX Ltd. (Cambridge, U.K.) raised $11 million in a series A round led by Medicxi...
...Medicxi on Feb. 9. Johnson & Johnson Innovation-JJDC Inc. also participated. SuperX Ltd. , Cambridge, U.K. Alex Himes SuperX Ltd....
BioCentury | Feb 9, 2017
Financial News

SuperX raises $11M series A round

...Anticoagulation play SuperX Ltd. (Cambridge, U.K.) raised $11 million in a series A round led by Medicxi...
...of bleeding. The company expects to begin clinical studies of its lead program in 2019. SuperX's...
...region of thrombin also dissociates anticoagulation from bleeding risk (see BioCentury, March 30, 2015) . SuperX...
Items per page:
1 - 4 of 4